AgomAb Therapeutics bags 21m Series A financing
AgomAb Therapeutics, a company resulting from a collaboration of argenx SE and growth factor experts from the University of Turin, has completed a 21m Series A financing.
Novartis acquires inflammasome blocker company IFM Tre
Novartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory diseases.
EMA recommends bluebird’s ?-thalassemia gene therapy
The European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its first meeting in Amsterdam.
Polyneuron Pharma raise CHF22.5m in Series A financing
The CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors.
Genfit prices IPO at $135m
French liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement.
Evotec partners with Mark Foundation for Cancer Research
Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs
BIO-Europe Spring: Partnering deluxe
The 13th annual BIO-Europe Spring international partnering conference will be held in Vienna, Austria, for the first time, March 2527, 2019, at the Messe Wien Exhibition and Congress Center. The event is highly regarded among companies across the life science value chain, from large biotech and pharma companies to financiers and innovative startups.
New approach to treat eye cancer
A research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer.
Pfizer buys stake in liver gene therapy player Vivet
Pfizer Inc has paid 45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801.
Sotio on track for 2nd Phase III trial
After positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate a global Phase III study with its autologous cell-based immunotherapy also in this indication.